ALLYCKA ESPIRITU

Outstanding knowledge and skills, with years of experience in clinical laboratory, with extensive knowledge of hematology, clinical microscopy, clinical chemistry and phlebotomy. Familiar with staining procedures, analyzing and reporting data and performing quality control.

Proactive and goal-oriented professional with excellent time management and problem-solving skills. Known for reliability and adaptability, with swift capacity to learn and apply new skills. Committed to leveraging these qualities to drive team success and contribute to organizational growth.

• A Multi-national, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy, safety and immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated for the prevention of COVID-19 in healthy adults aged 18 years and older.
• A phase III, Randomized, Active-controlled, Observer-blind, Parallel Group, Multi-Center Study to Assess the Immunogenicity and Safety of SK SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine adjuvanted with AS03(GBP510) in adults aged 18 years and older.
• CLO-SCB-2019-003 SPECTRA: Study evaluation Protective-efficacy and safety of Clover’s Trimeric Recombinant protein-based and Adjuvanted COVID-19 vaccine.
• A Phase 3 Multi-Center International, Randomized, Active-Controlled Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost with UB-612 Vaccine.
• A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection with Symptoms) in Adults Residing With a Person With COVID-19.